Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
7.22
-0.02 (-0.21%)
Aug 15, 2025, 2:59 PM - Market open
Abeona Therapeutics Revenue
Abeona Therapeutics had revenue of $400.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $400.00K.
Revenue (ttm)
$400.00K
Revenue Growth
n/a
P/S Ratio
928.48
Revenue / Employee
$2,941
Employees
136
Market Cap
369.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 3.50M | 2.09M | 147.52% |
Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
Dec 31, 2020 | 10.00M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ABEO News
- 1 day ago - Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 14 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients - GlobeNewsWire
- 4 weeks ago - ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - GlobeNewsWire
- 4 weeks ago - Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy - PRNewsWire
- 6 weeks ago - Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million - GlobeNewsWire
- 6 weeks ago - Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy - GlobeNewsWire
- 6 weeks ago - Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index - GlobeNewsWire